Axtria Thought Leadership
Executive insights and perspectives on the Life Sciences industry
Report
The Power Of Digital Technologies In Transforming Clinical Trials
Clinical trials are becoming more complex as pharmaceutical companies focus their research and development efforts on treatments for rare diseases and personalized medicine, and on ...
White Paper
COVID-19 Recession Effects On Pharmaceutical-Related Patient Health Outcomes
This white paper investigates the research framework to model the expected effects on the decline in health outcomes caused by a decrease in the quantity and quality of pharmaceuti ...
White paper
Should Pharmaceutical Incentive Compensation Plans Cap At-Risk Sales Rep Compensation?
This white paper looks at a simple but important research question – why do pharma companies have incentive compensation (IC) plans that cap their at-risk sales rep compensation? ...
White Paper
Coronavirus Pandemic Effects On Incentive Compensation
This paper focuses on coronavirus pandemic effects on IC for pharma companies in the short-term, medium-term, and long-term, while also providing prescriptive actions for sales exe ...
White Paper
Designing A Patient-Centric Commercial Strategy
This whitepaper addresses how RWE should be leveraged for informing various commercial decisions with a deeper-dive into marketing-mix analysis (MMx). ...
White Paper
How Will The Coronavirus Pandemic Affect The US Pharmaceutical Industry?
The outbreak of the coronavirus pandemic illustrates the inherent risks and uncertainties that are prevalent in the operation of complex and global business, as seen in the pharmac ...
White Paper
Can The Coronavirus Contagion Economically Infect The Global Pharmaceutical Industry?
Events surrounding the coronavirus contagion, characterized as a “black swan” event, which started in China, remain very fluid and are changing daily. No one really knows what ...
White Paper
What Are The Factors That Cause Call Plan Adherence To Fail And How To Address The Problem
The sales force for a pharma company still represents one of the largest line items in the budget and is the most significant driver of sales relative to all other individual sales ...
White Paper
One Important Lesson From Biogen’s Surprise Announcement On Hopes For An Alzheimer’s Drug
This white paper lays out the reasons for these changes and action steps executives must make to shift from the current volume-based to value/outcomes-based commercial model design ...
